Important information for our community: | |||
| COVID-19 Resource Center | Your Care During the Pandemic | ||
About Holy Name Medical Center201-833-3000
877-HOLY-NAME (465-9626)
201-833-3300
201-833-3187
201-833-7040
201-833-3352
For general questions or comments, email info@holyname.org
Learn more about these studies:
|
|
|
List of Clinical Studies |
|
| Oncology | |
| Study Name | Principal Investigator |
 |
|
|
NRG-GI004– Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A
Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or
without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients
with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer. Read more. |
Elan Diamond, MD |
|
|
|
S1815– A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus
Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Read more. |
Elan Diamond, MD |
|
|
| Oncology - Breast Cancer | |
| Study Name | Principal Investigator |
|
|
|
MK3475-756 – A randomized, double-blind, phase III study of Pembrolizumab vs. placebo in
combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the
treatment of high-risk early-stage estrogen receptor-positive, human epidermal growth factor
receptor 2-negative (ER+/HER2-) breast cancer (KEYNOTE-756). Read more. |
Yadyra Rivera, MD |
|
|
|
A011401– Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment
of Overweight and Obese Women with Early Breast Cancer. Read more. |
Elan Diamond, MD |
|
|
|
NRG-BR003– A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus
Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive
or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Read more. |
Elan Diamond, MD |
|
|
|
S1501– Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with
Metastatic HER-2+ Breast Cancer, Phase III. Read more. |
Yadyra Rivera, MD |
|
|
|
EA1131– A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs.
Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant
Chemotherapy. Read more. |
Yadyra Rivera, MD |
|
|
| Oncology - Prostate Cancer | |
| Study Name | Principal Investigator |
|
|
|
Ferring 108– A multi-center, randomized, assessor-blind, controlled trial comparing the
occurrence of major adverse cardiovascular events (MACEs) in patients with prostate cancer and
cardiovascular disease receiving Degarelix (GnRH receptor antagonist) or Leuprolide (GnRH
receptor agonist). Read more. |
Elan Diamond, MD |
|
|
|
EA8153– Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and
Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously
Treated With Docetaxel. Read more. |
Elan Diamond, MD |
|
|
